Leber Hereditary Optic Neuropathy—usually shortened to LHON—is an inherited eye condition that mainly affects the optic nerve, the cable that connects your eye to your brain. In LHON, tiny energy-making parts inside our cells called mitochondria don’t work properly, especially inside retinal ganglion cells (these are the nerve cells in the retina that send visual signals along the optic nerve). Because the mitochondria are not producing enough clean energy, these sensitive nerve cells come under oxidative stress, become weak, and start to die. When enough of these cells are lost, the optic nerve cannot carry a clear signal, and central vision (the sharp, straight-ahead vision used for reading and recognizing faces) fades—often painlessly and over weeks to months.
Unlike most genes, the main genetic instructions for LHON sit in mitochondrial DNA (mtDNA), which is passed from mother to all her children. That means both sons and daughters can inherit the risk, but young adult men are the most likely to actually lose vision. Many people who carry the LHON mutation never lose vision; others suddenly do—often after a trigger like smoking, heavy alcohol use, certain toxins/medicines, or illness. Usually one eye is affected first, and the other eye follows within weeks or months. Over time, the optic nerve looks pale (atrophy) because many nerve fibers have died.
How LHON develops (in very simple terms)
Faulty energy plant: A spelling change (mutation) in mtDNA disrupts Complex I of the mitochondrial “power chain.”
Energy gap + oxidative stress: Cells get less ATP (energy) and more free radicals.
Most vulnerable cell type: Retinal ganglion cells—especially those handling fine central vision—are the first to fail.
Optic nerve damage: As these cells die, the optic nerve thins and vision drops.
Why men more than women? Hormones and other biological factors may give women a bit of extra protection, so fewer women with the mutation lose vision.
Types of LHON
Classic (Primary) LHON: Sudden, painless loss of central vision in one eye, then the other, in a young adult. Caused by one of the well-known mtDNA mutations.
LHON “Plus”: Vision loss plus other nervous-system issues (for example tremor, movement problems, heart-rhythm issues, or features that look like multiple sclerosis).
Carrier (Unaffected) State: A person has the mtDNA mutation but normal vision. They still face risk if triggers pile up.
Subacute LHON: The early active phase—vision falls over weeks to a few months; the optic nerve may look a bit swollen with tiny abnormal blood vessels.
Chronic LHON: Months to years later—the optic nerve looks pale and thin; vision usually stabilizes at a lower level.
Homoplasmic vs Heteroplasmic LHON:
Homoplasmic = almost all mitochondria carry the mutation.
Heteroplasmic = a mix of normal and mutated mtDNA. More mutated copies usually means higher risk.
Early-onset LHON (childhood/teen) and Late-onset LHON (after age 50): Same disease biology, different timing.
Autosomal-recessive LHON-like disease (AR-LHON): A rare nuclear gene problem (for example in DNAJC30) can produce a very similar picture. It is inherited differently (from both parents, not just the mother).
Causes
Important idea: The root cause is a mitochondrial DNA mutation (or rarely a nuclear gene change). But many people with these mutations never lose vision. Extra “pushes” (triggers) make vision loss more likely. Below are both the underlying causes and the known triggers/modifiers.
mtDNA mutation in MT-ND4 (m.11778G>A): The most common primary mutation worldwide, disrupting Complex I.
mtDNA mutation in MT-ND6 (m.14484T>C): Another classic mutation; some have better chances of partial recovery.
mtDNA mutation in MT-ND1 (m.3460G>A): Less common than ND4, but well-established as a primary cause.
Other rare mtDNA Complex I mutations: Several less common changes in ND genes can cause an LHON picture.
Level of heteroplasmy: A higher percentage of mutated mtDNA raises the risk of expression.
Mitochondrial haplogroup background (e.g., J in Europe): Some mtDNA “backgrounds” make the same mutation more penetrant.
Nuclear genetic modifiers: Non-mitochondrial genes can modify risk, even when mtDNA carries the primary change.
Male sex: Men with mutations convert to vision loss more often than women.
Young adult age window: Peak risk is late teens to thirties, though any age is possible.
Cigarette smoking: One of the strongest, most consistent triggers; raises oxidative stress in mitochondria.
Heavy alcohol use: Also increases oxidative stress and mitochondrial strain.
Toxic alcohols/poisons (e.g., methanol, cyanide, carbon monoxide): Directly injure mitochondrial function and the optic nerve.
Certain medicines that impair mitochondria or the optic nerve (examples clinicians worry about include ethambutol, linezolid, and some older antibiotics/antiretrovirals).
Nutritional deficiency (B12, folate, thiamine, copper): Starves nerves of cofactors, worsening mitochondrial stress.
Severe anemia or hypoxia (including sleep apnea or high altitude): Less oxygen = more stress for already fragile cells.
Systemic infections or fever: Illness can tip the energy balance and raise oxidative stress.
Head trauma or major physiologic stress: Big stressors sometimes precede onset.
Thyroid overactivity or other endocrine stressors: Metabolic overdrive may nudge vulnerable cells over the edge.
Solvent/chemical exposure (industrial toxins): Adds oxidative load to optic nerves.
AR-LHON (DNAJC30 and others): A distinct, recessive pathway that looks like LHON but is not mtDNA-inherited.
Symptoms and signs
Painless central vision loss: The hallmark; words in the center blur or vanish.
Rapid change over weeks: One eye goes down first, the other often follows within months.
Central scotoma: A dark or fuzzy spot right where you try to look.
Reduced visual acuity: Trouble reading fine print even with glasses.
Color vision loss (especially red-green): Colors look dull; reds may seem brownish or washed out.
Poor contrast sensitivity: Gray on white or low-contrast letters become hard to see.
Normal or near-normal peripheral vision: Side vision may be relatively preserved.
No eye pain with movement: Helps distinguish from typical optic neuritis.
Light sensitivity (sometimes): Bright light can feel uncomfortable.
Difficulty recognizing faces: Because facial details rely on central vision.
Trouble reading and screen use: Central blur makes sustained reading hard.
Depth-perception problems: Picking up a cup or pouring water gets awkward.
Vision fluctuates a bit day-to-day early on: Fatigue or illness can make it feel worse.
Later optic disc pallor (clinician-observed): The nerve looks pale on eye exam months after onset.
In LHON “Plus,” extra neurologic symptoms: For example, balance or movement problems in addition to vision issues.
Diagnostic tests
(Each item explains what the test is, why it’s done, and what it shows in LHON.)
A) Physical exam and chair-side eye tests
Best-corrected visual acuity (Snellen/ETDRS):
What: Reading standardized letters with the best glasses correction.
Why: Measures how sharp central vision is.
LHON pattern: Significant drop in central vision, often to 20/200 or worse over time.
Pupil exam with swinging flashlight test (checks for RAPD):
What: Moving a light between eyes to see if one pupil reacts less briskly.
Why: Finds an afferent (incoming-signal) problem in the optic nerve.
LHON pattern: RAPD often present, especially early when one eye is worse.
Color vision testing (Ishihara or HRR plates):
What: Number or shape plates to detect color errors.
Why: LHON affects color vision early.
LHON pattern: Red-green defects and overall dyschromatopsia.
Contrast sensitivity (Pelli-Robson):
What: Letters that fade in contrast rather than size.
Why: Picks up visual quality loss that acuity alone can miss.
LHON pattern: Often reduced contrast, matching patient complaints.
Confrontation visual fields (by the clinician’s hands):
What: Quick bedside mapping of side vision.
Why: Screens for field defects.
LHON pattern: May suggest cecocentral loss; formal fields below are more precise.
Amsler grid (near-vision central grid):
What: A small square grid held at reading distance.
Why: Checks central distortion or blank spots.
LHON pattern: Central blur or a missing patch (scotoma).
Red-cap desaturation test:
What: Comparing how “red” a red cap looks with each eye.
Why: A quick, sensitive check for optic nerve dysfunction.
LHON pattern: The affected eye sees the cap as less vivid red.
Dilated fundus exam (ophthalmoscopy):
What: Direct view of the optic nerve and retina.
Why: Looks for structural changes.
LHON pattern: Early: peripapillary telangiectasias (tiny vessels) and RNFL swelling without leakage; Late: optic disc pallor (temporal > diffuse).
B) Formal/manual functional tests
Automated visual field testing (perimetry, e.g., Humphrey 24-2/10-2):
What: Machine maps where you can see tiny lights.
Why: Quantifies the field defect shape and depth.
LHON pattern: Central or cecocentral scotomas are typical.
Formal reading acuity and near-vision testing (e.g., MNREAD/Jaeger):
What: Measures reading speed and smallest readable print.
Why: Tracks the day-to-day impact on life.
LHON pattern: Slow reading with central loss and poor contrast tolerance.
C) Laboratory and pathological tests
Targeted mtDNA testing for the three primary mutations (ND4 11778, ND6 14484, ND1 3460):
What: A blood (or saliva) genetic test.
Why: Confirms the classic LHON mutation.
LHON pattern: One of these is found in most definite cases.
Comprehensive mtDNA sequencing (NGS) and heteroplasmy quantification:
What: Broader look for rare LHON-like mtDNA changes and the proportion of mutant mtDNA.
Why: Explains atypical cases and risk in relatives.
LHON pattern: Identifies rare ND gene variants and % mutant load.
Haplogroup typing (mtDNA background):
What: Classifies the maternal mtDNA lineage.
Why: Some backgrounds raise the chance of expression.
LHON pattern: Helps with risk counseling (does not change diagnosis).
Nuclear gene testing for AR-LHON (e.g., DNAJC30) when history suggests recessive inheritance:
What: A blood test for nuclear genes affecting Complex I repair.
Why: Catches LHON-like disease that is not maternally inherited.
LHON pattern: Positive in families with both-parent inheritance pattern.
Rule-out blood studies (B12, folate, thiamine, copper, CBC, ESR/CRP, thyroid panel):
What: Standard labs.
Why: Exclude nutritional, toxic, or inflammatory optic neuropathies that can mimic LHON or worsen it.
LHON pattern: Usually normal; abnormalities point to add-on problems to fix.
Toxicology/medication review (including methanol exposure panel when suspected):
What: History plus lab tests if needed.
Why: Toxins/medicines can cause or trigger optic neuropathy.
LHON pattern: Identifies modifiable triggers to stop immediately.
D) Electrodiagnostic tests
Visual Evoked Potentials (VEP):
What: Checks the brain’s electrical response to a visual pattern.
Why: Measures the optic pathway’s function.
LHON pattern: Often reduced amplitude (weak signal) with variable latency.
Pattern Electroretinogram (PERG):
What: Electrical test focused on retinal ganglion cell function.
Why: Differentiates optic-nerve/ganglion problems from photoreceptor disease.
LHON pattern: N95 component is reduced, matching ganglion-cell loss.
Full-field ERG (rod/cone function):
What: Tests photoreceptors across the retina.
Why: Should be normal in pure optic neuropathy; helps exclude retinal diseases.
LHON pattern: Typically normal, which supports an optic-nerve process.
E) Imaging tests
Optical Coherence Tomography (OCT) — RNFL and GCC:
What: A high-resolution scan of retinal layers.
Why: Objectively shows nerve fiber/ganglion cell thickness.
LHON pattern: Early: mild RNFL swelling and microvascular changes; Later: thinning of the temporal RNFL and macular ganglion cell complex.
OCT-Angiography (OCTA):
What: Non-dye scan of retinal blood flow.
Why: Looks for microvascular dropout.
LHON pattern: Reduced peripapillary capillaries matching nerve fiber loss.
Color fundus photography / red-free imaging:
What: Photos of the optic nerve and retina.
Why: Documents baseline and change over time.
LHON pattern: Early telangiectasias; later optic disc pallor.
Fundus autofluorescence (FAF):
What: Highlights metabolic stress in the retina.
Why: Sometimes shows subtle changes around the disc.
LHON pattern: Mild peripapillary signal changes; not diagnostic alone.
Fluorescein angiography (FA):
What: Dye test to see leaking vessels.
Why: Distinguishes true edema from pseudo-swelling.
LHON pattern: Little/no leakage from the disc (helps exclude inflammatory optic disc edema).
MRI of brain and orbits with contrast:
What: A magnetic scan of optic nerves and brain.
Why: Excludes mimics (e.g., demyelinating optic neuritis, compressive lesions).
LHON pattern: Often normal; mild optic-nerve signal change may appear in some.
Non-pharmacological treatments
Each item below includes Description → Purpose → Mechanism (in simple English).
Stop smoking → Cut conversion risk and further damage → Smoking poisons mitochondria and optic nerve; stopping removes a major toxin. PMC
Avoid heavy alcohol → Reduce trigger load → Alcohol and its metabolites stress mitochondria; heavy use correlates with onset/worse outcomes. Modern Optometry
Medication/toxin review → Lower avoidable mitochondrial stress → Your doctor screens TB drugs (e.g., ethambutol), linezolid, older antiretrovirals, solvents, cyanide/methanol sources, and avoids or monitors where possible. PMCaes.amegroups.org
Genetic counseling & family testing → Clarity + planning → Identifies carriers, explains maternal vs. recessive inheritance, and offers reproductive options.
Vision rehabilitation (low-vision clinic) → Regain function fast → Structured training + devices (magnifiers, CCTV, e-reader/apps, screen readers, contrast filters) tailored to your life goals; proven, guideline-backed care. AAOPMC
Eccentric viewing training → Use healthy retina off-center → Teaches you to fixate slightly away from the scotoma to read/navigate better.
Contrast & lighting optimization → Make details “pop” → Task lighting, high-contrast print, matte finishes, anti-glare lenses.
Digital accessibility toolkit → Read, study, work → Built-in phone/PC zoom, text-to-speech, high-contrast themes, shortcut gestures; modern assistive tech improves independence. AAO
Orientation & mobility training → Safe travel indoors/outdoors → Map routes, cane skills if needed, public transport access.
Workplace/school accommodations → Keep studying/working → Larger monitors, screen readers, extra time in exams, seating placement, duty adjustments.
Psychological support → Treat the emotional load → CBT/support groups reduce anxiety/depression; improves rehab engagement.
Occupational therapy at home → Daily task redesign → Labeling, organization systems, tactile cues, kitchen/bath safety.
Driving counseling → Safety + legal compliance → Clear advice about driving eligibility; switch to alternatives where required.
Exercise program (safe & regular) → Overall brain/retina health → Aerobic activity supports vascular health and stress control; no evidence for cure, but helpful for wellbeing.
Sleep hygiene → Energy management → Good sleep helps brain processing and day-to-day coping.
Nutrition pattern (see diet section) → Mitochondria-friendly pattern → Adequate calories, B-vitamins, antioxidants in food; avoid crash diets/toxins.
Protect from methanol/adulterated spirits → Prevent catastrophic optic injury → Use reputable sources; avoid home-distilled alcohol.
Occupational health measures → Minimize solvent/pesticide exposure → PPE, ventilation, job modifications if you’re a carrier working with chemicals. MDPI
Early-access/clinical trial discussion → Fair shot at innovation → You and your ophthalmologist can watch for gene therapy or other investigational programs when appropriate (details below). gensight-biologics.com
Reproductive options if you’re a female carrier → Reduce risk to children → UK-licensed mitochondrial donation (a specialized IVF) can reduce transmission risk; strict eligibility and regulation apply. HFEA+1
Drug treatments
Important: Only idebenone currently has regulatory approval (EU/UK) for LHON. Other drugs below are off-label or investigational; discuss locally available options, dosing, and monitoring with your ophthalmologist.
Idebenone (Raxone®) — short-chain benzoquinone; electron carrier/antioxidant
Dose/Time: 300 mg three times daily with food (total 900 mg/day), typically ≥12–24 months under specialist supervision.
Purpose: Improve the chance of visual stabilization or recovery, especially when started within the first year.
Mechanism (simple): Lets electrons “bypass” the weak complex I and reach complex III, helping struggling ganglion cells make energy again.
Key side effects: Mostly mild—diarrhea, cough, nasopharyngitis, back pain; harmless reddish-brown urine from metabolites; watch interactions (mild CYP3A4/P-gp effects). European Medicines Agency (EMA)CellCoenzyme Q10 (ubiquinone/ubiquinol) — antioxidant/electron shuttle
Dose/Time: Commonly 200–400 mg/day in divided doses (practice-based; off-label).
Purpose: Support mitochondrial redox; sometimes used if idebenone unavailable.
Mechanism: Accepts/donates electrons in the respiratory chain; theoretical support for stressed mitochondria. (Evidence weaker than idebenone.)EPI-743 (Vatiquinone) — redox-active para-benzoquinone; investigational
Dose/Time: Regimens in mitochondrial disease studies often 100–400 mg, 2–3×/day; LHON evidence remains limited.
Purpose: Potent cellular NQO1-targeted redox modulation; explored for mitochondrial disorders.
Mechanism: Rebalances oxidative stress and glutathione pathways; not yet approved for LHON. ClinicalTrials.govElamipretide (SS-31, MTP-131) — mitochondria-targeting peptide; investigational
Dose/Time: Topical 1% eye drops, often twice daily in trials (frequency varied; not approved).
Purpose: Try to stabilize inner mitochondrial membranes (cardiolipin) and reduce oxidative injury.
Mechanism: Binds cardiolipin to improve electron transport efficiency; human LHON data are early. PubMedCiticoline (CDP-choline) — neuroprotective metabolic support; off-label
Dose/Time: 500–1,000 mg/day oral (continuous courses used in optic neuropathies).
Purpose: Support neuron membrane repair and neurotransmission; small studies in optic nerve diseases suggest functional benefits.
Mechanism: Boosts phospholipid (phosphatidylcholine) synthesis and dopamine pathways. PMCRiboflavin (vitamin B2) — cofactor for redox enzymes; supplement/adjunct
Dose/Time: 100–200 mg/day with food.
Purpose: Support complex I/II function and antioxidant enzymes.
Mechanism: Precursor for FAD/FMNs used throughout mitochondrial metabolism.Thiamine (vitamin B1) — mitochondrial pyruvate metabolism support
Dose/Time: 50–100 mg/day.
Purpose: Prevent cofactor deficiency that worsens neuronal energy failure.
Mechanism: Cofactor for pyruvate dehydrogenase.Nicotinamide (vitamin B3) / Niacinamide — NAD⁺ precursor
Dose/Time: 500–1,000 mg/day (monitor liver function at higher doses).
Purpose: Support NAD⁺ pool; neuroprotection seen in other optic neuropathies; LHON-specific evidence limited.
Mechanism: Fuels mitochondrial redox reactions.Acetyl-L-carnitine — fatty-acid shuttle to mitochondria
Dose/Time: 500–1,000 mg, 2–3×/day.
Purpose: Nurture energy production when mitochondria are stressed.
Mechanism: Transports long-chain fatty acids into mitochondria for ATP generation.Alpha-lipoic acid — antioxidant/redox cycling
Dose/Time: 300–600 mg/day.
Purpose: Reduce oxidative stress; widely used in neuropathies, LHON-specific data limited.
Mechanism: Recycles other antioxidants; cofactor for mitochondrial enzymes.
Why these nine adjuncts? They’re commonly used to support mitochondrial function in clinical practice when idebenone is unavailable or as add-ons. Evidence ranges from limited to modest—always use with medical guidance.
Dietary / molecular and other supportive supplements
Note: These do not cure LHON. They’re supportive, aiming to reduce oxidative stress and keep mitochondria nourished. Always check for drug interactions and medical contraindications.
Ubiquinone/Ubiquinol — 100–200 mg twice daily → Antioxidant/electron carrier → Supports respiratory chain.
Nicotinamide (B3) — 500–1,000 mg/day → NAD⁺ support → Fuels redox enzymes.
Riboflavin (B2) — 100–200 mg/day → FAD/FMN cofactor → Aids complex I/II.
Thiamine (B1) — 50–100 mg/day → PDH cofactor → Improves carbohydrate-to-energy flow.
Pyridoxal-5-phosphate (active B6) — 25–50 mg/day → Neurotransmitter synthesis → Helps neuronal metabolism.
Methylfolate (active folate) — 1–5 mg/day → One-carbon metabolism → Supports DNA repair/methylation.
Vitamin C — 250–500 mg/day → Antioxidant → Scavenges free radicals; often co-administered with idebenone in practice.
Vitamin E (mixed tocopherols) — 200–400 IU/day → Lipid antioxidant → Protects membranes.
Acetyl-L-carnitine — 500–1,000 mg 2–3×/day → Fatty-acid shuttle → Energy production.
Alpha-lipoic acid — 300–600 mg/day → Antioxidant/cofactor → Regenerates other antioxidants.
Creatine monohydrate — 3–5 g/day → Energy buffer → Boosts phosphocreatine in neurons.
Omega-3 DHA/EPA — 1–2 g/day combined → Membrane health → Anti-inflammatory lipid milieu.
Magnesium — 200–400 mg elemental/day → ATP biology → ATP needs Mg²⁺; helps neuromuscular function.
S-adenosyl-L-methionine (SAMe) — 400–800 mg/day → Methylation/antioxidant → Supports cellular repair.
Resveratrol or polyphenol mix — per label → Antioxidant signaling → Activates mitochondrial biogenesis pathways (e.g., sirtuins) in models.
Advanced” therapies
Lenadogene nolparvovec (LUMEVOQ®) — AAV2-ND4 gene therapy
What it is: A viral vector carrying a working copy of ND4 is injected into the eye to make the missing protein.
Status (Aug 2025): Not approved anywhere; the company withdrew its 2023 EMA application, is reworking manufacturing and planning new studies; France is discussing a named early-access route after a dose-ranging study.
Dose/How: One-time intravitreal injection per eye in trials.
Mechanism: Allotopic expression—ND4 is made in the nucleus, then shuttled to mitochondria to support complex I.
Safety/Notes: Trials suggest bilateral effects after one-eye dosing; access limited to trials/early-access programs. European Medicines Agency (EMA)gensight-biologics.com+1Elamipretide (SS-31) — mitochondria-targeting peptide
Form/Dose: Topical 1% drops (trial dosing varied).
Goal: Stabilize cardiolipin and improve energy handling in RGCs.
Status: Investigational; no approval for LHON. PubMedEPI-743 (Vatiquinone) — powerful redox modulator
Form/Dose: Oral (100–400 mg 2–3×/day in studies of other mitochondrial diseases).
Goal: Amplify antioxidant defenses (glutathione/NQO1 axis).
Status: Investigational in LHON. ClinicalTrials.govMesenchymal stem cell (MSC)-based approaches — cell or exosome therapy
Concept: MSCs may secrete trophic factors or transfer mitochondria to stressed neurons.
Evidence: Small, mixed-quality studies and meta-analyses across optic neuropathies suggest possible acuity gains, but safety, durability, and proper patient selection remain unclear; authoritative groups caution against clinical use outside trials.
Status: Experimental; consider registered trials only. BioMed CentralFrontiersAAOEncapsulated cell therapy (neurotrophic factors) — implant releasing CNTF etc.
Concept: A tiny implanted device releases protective proteins to nourish RGCs.
Status: Investigational in other retinal diseases; not established for LHON.NAD⁺ boosters (e.g., nicotinamide riboside) — metabolic modulation
Concept: Raise neuronal NAD⁺ to improve resilience.
Status: Early-stage/adjunctive; not disease-modifying evidence in LHON yet.
Surgeries for LHON
Short answer: no. There is no eye surgery that repairs the optic nerve or fixes the LHON mutations. However, a few procedures can be relevant:
Intravitreal gene therapy injection (if in a trial): technically a procedure, not a drug pill; still experimental (see above). European Medicines Agency (EMA)
Cataract surgery (if you also have a cataract): this clears lens clouding so the remaining vision is as sharp/bright as possible; it doesn’t treat LHON itself.
Low-vision device fittings (not “surgery,” but in-clinic procedures) for custom telescopes or high-add systems.
No role for optic nerve decompression or glaucoma surgery unless there’s a separate disease that requires it.
Reproductive “surgery” to prevent transmission: mitochondrial donation (pronuclear transfer) for female carriers in the UK, under strict licensing—this is an IVF procedure to reduce risk to future children, not to treat the parent’s eyesight. HFEA
Prevention strategies
Don’t smoke (ever).
Avoid heavy alcohol; keep intake low or abstain.
Discuss risky medicines (e.g., ethambutol, linezolid) with your doctors before starting them.
Avoid methanol/adulterated spirits; buy alcohol from trusted sources only.
Use PPE/ventilation if you work with solvents/pesticides.
Eat adequately (no crash diets); keep B-vitamins sufficient.
Control other health stressors (infections, severe anemia, malnutrition).
Family counseling/testing so relatives can modify risks.
Early ophthalmology referral for any central blur—sooner is better if idebenone is considered.
Female carriers: learn about mitochondrial donation/PGT options well before pregnancy. PMCMDPIHFEA
When to see a doctor—exactly
Immediately (same-day/next-day) if you have sudden, painless central blur in one eye, especially with color loss.
Urgently if the second eye starts to blur.
Soon if you have a family history of LHON and notice any new visual symptom.
Pre-emptively (genetics + counseling) if you’re a maternal relative of an affected person or considering pregnancy.
What to eat
Eat more of:
Leafy greens (folate, antioxidants).
Legumes/whole grains (B-vitamins).
Eggs, dairy, fish (B12, high-quality protein).
Colorful fruits/veg (vitamin C, carotenoids, polyphenols).
Fatty fish or flax/chia (omega-3s).
Limit/avoid:
6) Alcohol (especially spirits; avoid any non-commercial source).
7) Tobacco in all forms (smoked, chewed).
8) Cassava that’s not properly processed (cyanide risk).
9) Highly processed trans-fat snacks (pro-oxidative diet pattern).
10) Mega-dosing supplements without medical advice (possible toxicity/interactions).
(These support general mitochondrial health; they don’t replace medical treatment.)
Frequently asked questions
1) Is LHON the same as optic neuritis?
No. LHON is painless and mitochondrial, while typical optic neuritis (often linked to MS) usually hurts with eye movement and is inflammatory.
2) Can women pass LHON to children?
For mtDNA LHON, yes—mothers pass mitochondria to all children; fathers do not. arLHON (DNAJC30) follows autosomal-recessive rules (both parents must carry the gene). World Health Organization
3) If I carry a mutation, will I definitely go blind?
No. Many carriers never become affected. Smoking and heavy alcohol increase risk—so avoiding them matters. PMC
4) Does idebenone work for everyone?
No medicine works 100% of the time. Best odds are when started early (ideally within 1 year). It has a favorable safety profile. European Medicines Agency (EMA)Cell
5) How long should I take idebenone?
Specialists often treat for 12–24 months and monitor vision/OCT. Follow your prescriber’s plan. European Medicines Agency (EMA)
6) What about gene therapy?
Promising but not approved as of August 2025; access mainly via trials or early-access programs in specific countries. European Medicines Agency (EMA)gensight-biologics.com
7) Are steroids helpful?
No. LHON is not an inflammatory optic neuritis. Steroids are not standard and can delay correct diagnosis.
8) Can diet or vitamins cure LHON?
No. A good diet and certain supplements may support mitochondrial function, but do not reverse the mutation.
9) Are there eye drops for LHON?
Not approved. Some investigational drops (e.g., elamipretide) are in trials. PubMed
10) Can I keep working or studying?
Often yes—with vision rehab, assistive tech, and reasonable accommodations. AAO
11) Will glasses fix LHON?
No—this is a nerve problem, not a focusing problem—but the right prescription helps you get every last bit of remaining clarity.
12) Is surgery an option?
There’s no curative surgery for the optic nerve. See the surgery section above.
13) Can stress trigger LHON?
Stress doesn’t cause LHON, but poor sleep/nutrition and increased toxin use (smoking/alcohol) during stress can raise risk.
14) Do colored filters help?
Many people like amber/yellow or contrast-enhancing filters for glare and contrast; low-vision clinics will test which tints help you most.
15) What can families do right now?
Test at-risk relatives, stop smoking, reduce alcohol, book vision rehab, and talk to a genetics professional about reproductive options (where legal, e.g., UK mitochondrial donation). HFEA
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: August 10, 2025.
Leber Congenital Amaurosis
